Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

On Q3 Earnings Call, Lilly Vows To Stay Its Current Course Despite Late-Stage Pipeline Setbacks

This article was originally published in The Pink Sheet Daily

Executive Summary

As analysts call for transformative M&A, executives talked up Lilly's modest diversification efforts, including its animal health business, Elanco, and strong Japanese sales.

You may also be interested in...



Alcresta Investment Reflects Omega Market Growth

Alcresta is developing omega-3 and -6 fatty acid supplements that are more easily digested and absorbable. Founders Alexey Margolin and Robert Gallotto look to repeat the success they had in 2010 when they sold an earlier nutritionals start-up for $180 million.

Alcresta Investment Reflects Omega Market Growth

Alcresta is developing omega-3 and -6 fatty acid supplements that are more easily digested and absorbable. Founders Alexey Margolin and Robert Gallotto look to repeat the success they had in 2010 when they sold an earlier nutritionals start-up for $180 million.

Servier, MacroGenics Forge Option Deal For Cancer Drug

The French pharma acquires the right to license the antibody MGA271, which has received strong interest since BMS’s Yervoy was approved in March.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel